Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as (BMS-562086)
Pexacerfont · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| pexacerfont | DRUG | Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks |
| escitalopram | DRUG | Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks |
| placebo | DRUG | Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks |
Inclusion Criteria: * Outpatient women ages 18-65 meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSM-IV TR) criteria for Generalized Anxiety Disorder (GAD), either moderate or severe (300.02) Exclusion Criteria: * Males * Patients who report a...
Pexacerfont was studied for the treatment of generalized anxiety disorder and major depressive disorder. It is a small molecule developed by Bristol-Myers Squibb and reached Phase 2 clinical development. It is investigational and has not been approved for any indication.
Pexacerfont targets CRHR1, the corticotropin-releasing hormone receptor 1. It acts as an antagonist at this receptor. This target is associated with the stress response and has been explored in psychiatric conditions such as generalized anxiety disorder and major depressive disorder.
Pexacerfont is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the clinical trials of the drug in generalized anxiety disorder and major depressive disorder.
Pexacerfont is in Phase 2 development. It has completed a Phase 2 trial in generalized anxiety disorder and a Phase 1 trial in major depressive disorder. It is investigational and has not been approved by the FDA for any indication.
Pexacerfont has been studied in two completed trials: NCT00481325, a Phase 2 trial in outpatients with generalized anxiety disorder, and NCT00135421, a Phase 1 trial in outpatients with major depressive disorder. Both were conducted in the United States and enrolled adult women.
Yes, Pexacerfont is also known as BMS-562086. Both names refer to the same investigational small molecule developed by Bristol-Myers Squibb for generalized anxiety disorder and major depressive disorder.